Abstract:HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.Tissue distributions profiles and plasma concentration–time curves in mice of 4r, 10m, and 19f; detailed experimental procedures for the synthesis of analogues 10a, 10b, 10i, 10j, 10k and intermediates 18h–18n; characterization (1H NMR spectra and 13C NMR spectra are attached) and HPLC purity control of the selected final compounds 10l, 10m, 18a, 18b, 18d, 18e, 18g, 19a–19h (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">PDF</a>)Molecular-formula strings of the reported compounds and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovery Of (1h-Pyrazolo[3,4-C]Pyridin-5-Yl)Sulfonamide Analogues As Hepatitis B Virus Capsid Assembly Modulators By Conformation Constraint

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators

A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation

Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Synthesis and Anti-Hepatitis B Virus Activity of Novel Benzimidazole Derivatives

Synthesis and Anti‐HBV Activities Evaluation of New Ethyl 8‐imidazolylmethyl‐7‐hydroxyquinoline‐3‐carboxylate Derivatives in Vitro